PEPTIDEPEDIA
Mitmachen
AOD-9604 + Tesamorelin marketed blend illustration
Vermarktete Mischung
B 0022026-08-08

AOD-9604 + Tesamorelin marketed blend

Alle MischungenAOD-9604Tesamorelin
Idealisierte Strukturdarstellung für AOD-9604 + Tesamorelin marketed blend
B 002AOD-9604 · Tesamorelin

Aus der Sequenz aufgebautes idealisiertes Konformer; keine experimentell bestimmte oder vorhergesagte Struktur.

Der Beweisinhalt wird in englischer Sprache gepflegt.

Bottom line

AOD-9604 + Tesamorelin is marketed by one seller as "BURN 24" and appears as a component pairing in other listings. Clinics also use broader "Fat Burner" labels for materially different mixtures that add MOTS-c and/or Ipamorelin. No published study of the exact two-component or wider marketed formulations was identified.

No established or recommended human dose. Reported amounts below are market observations, not guidance.

Name and formulation variability

Observed source/dateClaimed componentsClaimed amountsVerification limits
Genetic Peptide, "BURN 24" (2026)AOD-9604, Tesamorelin3 / 10 mgSingle-vendor name; identity and contents not independently verified
Elite Health HRT, "Fat Burner" variant (2026)AOD-9604, Tesamorelin, MOTS-cAmounts not consistently publishedClinic-declared wider component set; not equivalent to BURN 24
InShapeMD Texas, "Fat Burner" variant (2026)AOD-9604, Tesamorelin, Ipamorelin, with or without MOTS-cAmounts not consistently publishedClinic marketing name applied to a different three- or four-component set

"BURN 24" is a single-vendor name. "Fat Burner" is a broad marketing category rather than a reproducible formulation and may include additional components.

Component evidence

ComponentSeparate evidenceEvidence for combinationCompatibility/stability evidence
AOD-9604See component monographNone identified for the two-component or wider variantsNone identified
TesamorelinSee component monograph; product-specific label evidence does not transfer to a mixtureNone identified for the two-component or wider variantsNone identified
MOTS-cPresent only in wider clinic variants; see monographNone identified for the wider variantsNone identified
IpamorelinPresent only in wider clinic variants; see monographNone identified for the wider variantsNone identified

Combination-specific studies

No published peer-reviewed study of BURN 24 or the cited "Fat Burner" component sets was identified. The names and claimed formulations are documented only as market observations.

Safety and interaction uncertainties

  • Two-, three-, and four-component products share adjacent marketing language but are not equivalent.

  • No combination-specific human safety, interaction, , or toxicology data were identified.

  • Product identity, purity, sterility, and co-formulation stability cannot be inferred from a listing.

  • A fixed multi-component product complicates attribution of unexpected effects.

Regulatory and product-quality notes

  • "BURN 24" and "Fat Burner" are marketing names, not regulatory or pharmacopoeial standards.

  • Tesamorelin's product-specific status does not extend to seller-created mixtures.

  • The cited vendor and clinic pages are low-quality evidence and do not establish efficacy, approval, or suitability for humans.

Evidence gaps

  • No combination-specific controlled study

  • No stable definition for the wider "Fat Burner" variants

  • No independent identity or content verification

  • No published compatibility or stability data

Sources

  1. Genetic Peptide. BURN 24 market page. https://geneticpeptide.com/ accessed 2026-08-08.

  2. Elite Health HRT. Fat Burner blend clinic page. https://elitehealthhrt.com/ accessed 2026-08-08.

  3. InShapeMD Texas. Fat Burner blend clinic page. https://inshapemdtx.com/ accessed 2026-08-08.

Expertenstimmen

Was Experten sagen

Kommentare sind Meinungen und nicht Teil der Evidenzprüfung; eine Aufnahme bedeutet keine Befürwortung.

Für diese Verbindung wurde kein verifizierter Expertenkommentar in den Quellen gefunden, die dieser Atlas akzeptiert — peer-reviewte Literatur, Mitteilungen von Universitäten, Krankenhäusern und medizinischen Fachgesellschaften, Behörden sowie wissenschaftlicher Journalismus mit namentlicher Autorenschaft.

Das Fehlen von Kommentaren ist kein Beleg für oder gegen die Verbindung.

Aussagen von Anbietern, Kliniken und aus sozialen Medien sind grundsätzlich ausgeschlossen und werden nicht als Kommentare gezählt.

Für diese Verbindung wurden keine verifizierten Expertenvideos in den Quellen dieses Atlasses gefunden.

Das Fehlen von Videokommentaren ist kein Beleg für oder gegen die Verbindung.

Videos von Anbietern und aus sozialen Medien sind grundsätzlich ausgeschlossen und werden nicht gezählt.

Fragen

What does BURN 24 contain?

The identified single-seller listing names AOD-9604 and tesamorelin. BURN 24 is not an independently standardized market name.

Are Fat Burner peptide products the same as BURN 24?

Not necessarily. Observed clinic products with the broader label add MOTS-c, Ipamorelin, or both, so they are materially different three- or four-component formulations.

Has the exact AOD-9604 and Tesamorelin mixture been studied?

No published peer-reviewed study of BURN 24 or the cited wider component sets was identified. The pages document marketing only.

Does tesamorelin evidence establish how BURN 24 behaves?

No. Product-specific evidence about tesamorelin alone cannot establish the safety, compatibility, or performance of a seller-created mixture.

What remains unknown about BURN 24 and related products?

Combination safety, interactions, pharmacokinetics, toxicology, identity, purity, sterility, compatibility, stability, and cross-product equivalence were not established.